CanniMed Therapeutics Inc. Announces Director Resignation
November 20 2017 - 6:50AM
Business Wire
CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed”) announces
that, effective November 17, 2017, Mr. Rob Duguid has resigned from
the Board of Directors. The Company thanks Mr. Duguid for his
service on the board since 2001 and wishes him well in the
future.
About CanniMed Therapeutics Inc.
CanniMed is a Canadian-based, international plant
biopharmaceutical company and a leader in the Canadian medical
cannabis industry, with 16 years of pharmaceutical cannabis
cultivation experience, state-of-the-art, GMP-compliant production
process and world class research and development platforms with a
wide range of pharmaceutical-grade cannabis products. In addition,
the Company has an active plant biotechnology research and product
development program focused on the production of plant-based
materials for pharmaceutical, agricultural and environmental
applications.
CanniMed, through its subsidiaries, was the first producer to be
licensed under the Marihuana for Medical Purposes Regulations, the
predecessor to the current Access to Cannabis for Medical Purposes
Regulations. It was the sole supplier to Health Canada under the
former medical cannabis system for 13 years, and has been producing
safe and consistent medical cannabis for thousands of Canadian
patients, with no incident of product diversion or recalls.
For more information, please visit our websites: www.cannimed.ca
(patients) and www.cannimedtherapeutics.com (investors).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171120005475/en/
CanniMed Therapeutics Inc.Dara Willis,
416-836-9272media@cannimed.com